Dopamine neurons in the ventral tegmental area (VTA) represent a critical site of synaptic plasticity induced by addictive drugs. Orexin/hypocretin-containing neurons in the lateral hypothalamus project to the VTA, and behavioral studies have suggested that orexin neurons play an important role in motivation, feeding, and adaptive behaviors. However, the role of orexin signaling in neural plasticity is poorly understood. The present study shows that in vitro application of orexin A induces potentiation of N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission via a PLC/PKC-dependent insertion of NMDARs in VTA dopamine neuron synapses. Furthermore, in vivo administration of an orexin 1 receptor antagonist blocks locomotor sensitization to cocaine and occludes cocaine-induced potentiation of excitatory currents in VTA dopamine neurons. These results provide in vitro and in vivo evidence for a critical role of orexin signaling in the VTA in neural plasticity relevant to addiction.
Introduction
Drugs of abuse can alter synaptic plasticity in the mesolimbic dopamine system, a region that is implicated in a variety of addictive behaviors. In particular, long-lasting changes at excitatory synapses in the nucleus accumbens and the VTA result from in vivo administration of drugs of abuse (Fitzgerald et al., 1996; Thomas et al., 2001; Ungless et al., 2001; Borgland et al., 2004) . The lateral hypothalamus (LH) sends a substantial projection to the VTA (Fadel and Deutch, 2002; Baldo et al., 2003) and is a critical element in motivation and reward circuits activated by drugs of abuse, including cocaine (Wise, 1996) .
Orexins (hypocretins) are neuropeptides synthesized in neurons of the LH that can elicit arousal, feeding, and appetitive behaviors (DeLecea et al., 1998; Sakurai et al., 1998) . There are two known orexins, A and B, whose actions are mediated by two G protein-coupled receptors, termed orexin receptor type 1 (OXR1) and type 2 (OXR2); OXR1 shows higher affinity for orexin A, while OXR2 shows equal affinity for the two ligands (Sakurai et al., 1998) .
Dopamine neurons in the VTA are critical for a similar repertoire of motivated behaviors. In addition, excitatory synaptic transmission in VTA dopamine neurons is an important locus of neural plasticity induced by psychostimulant administration. Several lines of evidence suggest that orexin modulates dopaminergic neurotransmission. First, terminals of LH orexin neurons are apposed to dendrites and somata of dopaminergic VTA neurons (Fadel and Deutch, 2002) . Second, the dopamine receptor antagonist haloperidol blocks hyperlocomotion and stereotypy induced by intracerebroventricular orexin (Nakamura et al., 2000) . Finally, orexin increases the firing rate of VTA neurons (Korotkova et al., 2003) . Taken together, these results suggest that endogenous orexin signaling in dopamine neurons is an important substrate for the expression of motivated behaviors. However, the contribution of orexin signaling to VTA neural plasticity has not been investigated.
Glutamatergic transmission in the VTA plays a key role in neural plasticity relevant to addiction (Carlezon and Nestler, 2002; Kauer, 2004) . In particular, the induction of behavioral sensitization, a model used to assess addictive substances, is dependent upon activation of N-methyl-D-aspartate receptors (NMDARs) in the VTA (Vanderschuren and Kalivas, 2000) . NMDARs mediate long-term plasticity at a variety of excitatory synapses, and their activation promotes burst firing in VTA neurons and optimizes dopamine release (Komendantov et al., 2004) . To elucidate potential contributions of orexin signaling to neural plasticity in the VTA, we examined the effects of orexin A signaling on excitatory synapses of VTA dopamine neurons.
Results

Orexin A Potentiates NMDAR EPSCs in Dopamine Neurons
Excitatory postsynaptic currents (EPSCs) were recorded from VTA neurons in rat midbrain slices. EPSCs were evoked while holding neurons in voltage clamp at +40 mV. Measurements were taken 20 ms after the stimulus artifact, a time point at which the glutamatergic EPSC is mediated purely by NMDARs. Bath application of orexin A for 5 min resulted in a 49% 6 9% potentiation of NMDAR-mediated EPSCs ( Figure 1A , n = 12, 10/12 neurons had potentiation greater than 10%). This potentiation was concentration dependent (Figure 1B, 1 nM: 5% 6 1%, n = 6; 10 nM: 18% 6 3%, n = 6; 100 nM: 42% 6 5%, n = 6) and was significantly inhibited by the selective OXR1 receptor antagonist SB 334867 ( Figure 1C , 1 mM, n = 8, p < 0.01) although not completely blocked, suggesting the presence of OXR2 as well. AMPAR-mediated EPSCs recorded at 270 mV were not changed by orexin A ( Figure 1D , n = 8). Application of orexin A (100 nM) for 30 min resulted in a 74% 6 16% potentiation of NMDAR EPSCs that lasted longer than 40 min after washout ( Figure 1E , n = 6). Orexin Ainduced potentiation of NMDAR EPSCs, but not AMPAR EPSCs, suggests that orexin-mediated potentiation occurs through a postsynaptic mechanism.
The VTA is composed of a heterogeneous collection of cell types, distinguished in part by neurotransmitter content. In addition to principal neurons, which are mostly dopaminergic, there are secondary and tertiary neurons that are mostly GABAergic (Cameron et al., 1997; Margolis et al., 2003) . To determine whether the neurons showing orexin A-induced potentiation were indeed dopaminergic, we filled neurons with biocytin while recording EPSCs and subsequently processed slices for tyrosine hydroxylase (TH). In TH-containing neurons, orexin A potentiated NMDAR responses in 7/8 neurons ( Figure 1F ). Of the two neurons that did not express TH, neither responded to orexin A. Thus, orexin A-induced potentiation of NMDAR-mediated EPSCs is found primarily in VTA dopamine-containing neurons.
Orexin A Potentiates NMDAR EPSCs via a PKC/PLC-Dependent Mechanism
In the next set of experiments, we sought to identify the intracellular pathway through which OXR1 activation leads to NMDAR potentiation. We loaded the patch pipette with the PLC inhibitor U-73122 (1 mM, Figures 2A  and 2C , n = 6) or the PKC inhibitor chelerythrin (1 mM, Figures 1A and 1B, n = 6). In both cases, the potentiation of (A) Orexin A (100 nM) increases NMDAR EPSCs evoked at +40 mV (n = 12, 10/12 neurons significantly potentiated). Inset shows representative traces of NMDAR EPSCs before and 25 min after application of orexin A. Scale bars, 50 pA, 50 ms. (B) Orexin A dose-dependently increases NMDAR EPSCs. Each bar represents the mean and SEM of EPSCs over a period of 2 min, 25 min after application of orexin A at concentrations of 1 (n = 6, p < 0.05), 10 (n = 6, p < 0.001), and 100 nM (n = 6; p < 0.001, one-way ANOVA, peak concentration effect versus baseline). (C) Orexin A-mediated increase in NMDAR EPSCs is blocked by the selective OXR1 antagonist SB 334857 (1 mM; n = 8).
(D) Orexin A (100 nM) does not increase AMPAR EPSCs evoked at 270 mV (n = 8). Inset shows representative traces of AMPAR EPSCs before and 25 min after application of orexin A. Scale bars, 20 pA, 20 ms. (E) After a 30 min application, orexin A (100 nM) increases NMDAR EPSCs for a prolonged period of time (n = 6). (F) Orexin A increases NMDAR EPSCs in TH-positive cells (7/8 TH+ neurons were orexin A responders, 1/8 TH+ did not respond, and 2/2 were TH2 and nonresponders). TH was labeled with anti-tyrosine hydroxylase antibodies and FITC. Biocytin was labeled with streptavidinconjugated Texas Red. Error bars represent SEM. NMDAR-mediated EPSCs by 100 nM orexin A was completely blocked. Next, the protein kinase A inhibitor PKI (20 mM, Figures 2D and 2F , n = 8) or Rp-cAMPs, a blocker of cAMP (100 mM, Figures 2D and 2E , n = 5), was added to the patch pipette. In these experiments, robust potentiation of NMDAR-mediated EPSCs occurred after orexin A application. Taken together, these data indicate that orexin A potentiates NMDARs in VTA dopamine neurons through a PLC/PKC-dependent pathway.
Orexin A Modulates NMDAR Subunit Composition
NMDARs are composed of an obligatory NR1 subunit and at least one NR2A, -B, -C, or -D subunit (Cull-Candy et al., 2001) . Changes in NMDAR subunit composition confer distinct gating and pharmacological properties on heteromeric NMDARs (Cull-Candy et al., 2001) , and a switch in subunit composition may alter synaptic function (Liu et al., 2004; Erreger et al., 2005) . We therefore sought to determine which type of NR2 subunit mediates orexin A-induced potentiation of NMDA responses.
Bath application of the NR2A/C antagonist NVP-AAM077 (0.4 mM; Liu et al., 2004; PEAQX, Feng et al., 2004) inhibited NMDAR EPSCs by 54% 6 7% and did not cause any further decrease of the current over the duration of application (40 min, n = 6). The ability of 100 nM orexin A to potentiate NMDAR-mediated EPSCs was significantly reduced in the presence of NVP-AAM077 ( Figure 3A , n = 7, maximum potentiation = 20% 6 6%, p < 0.05). To determine whether the NR2A/ C antagonist could block expression of orexin A-mediated potentiation of NMDAR EPSCs, we applied NVP-AAM077 (0.4 mM) during the peak increase of NMDAR EPSCs induced by 100 nM orexin A application. Accordingly, NVP-AAM077 blocked orexin-mediated potentiation of NMDAR EPSCs ( Figure 3B , n = 6, remaining current = 87% 6 11%). Further, we tested the effects of orexin A in the presence of Zn 2+ , a high-affinity selective inhibitor of NR1-NR2A receptors (Paoletti et al., 1997) . Zn 2+ inhibited NMDAR EPSCs by 13% 6 8% (100 nM, Figure 3C , n = 6) and by 29% 6 9% (300 nM, Figure 3C , n = 5, p < 0.05). Potentiation of NMDARs was significantly reduced in the presence of Zn 2+ ( Figure 3C , n = 5, maximum potentiation = 14% 6 4%, p < 0.05). To determine the potential involvement of NR2B-containing subunits in orexin A-mediated potentiation of NMDAR EPSCs, we measured orexin A responses in the presence of the bath-applied NR2B antagonist ifenprodil (3 mM). The remaining current after ifenprodil application was 71% 6 6%. In the absence of NR2B-containing NMDAR, orexin A (100 nM) potentiated NMDAR-mediated EPSCs by 36% to a maximum amplitude of 107% 6 16% ( Figure 3D , n = 6) of baseline EPSCs. When both NR2A/C and NR2B inhibitors were coapplied, orexin A (100 nM) potentiation of NMDAR EPSCs was largely inhibited ( Figure 3E , n = 6, orexin potentiation: 32% 6 5% to 45% 6 12%, p > 0.05). To determine whether the residual potentiation observed in the presence of NVP-AAM077 or Zn 2+ could be blocked, we recorded the effects of orexin A after coapplication of the NR2A/C and NR2B inhibitors in addition to the NR2C/D-preferring antagonist PPDA (1 mM ; Feng, et al., 2004) . PPDA further inhibited NMDAR EPSCs by an additional 10% (remaining current = 14% 6 2.2%, n = 6, Figure 3F ), and orexin A (100 nM) did not alter the remaining current in the presence of these blockers. Orexin A Translocates NMDARs to the Synapse Activation of PKC is implicated in NMDAR-dependent long-term potentiation (Malinow et al., 1989) , and it modulates NMDAR trafficking to the membrane (Lan et al., 2001; Scott et al., 2001; Fong et al., 2002) . NMDARs can translocate from intracellular or extrasynaptic pools to synaptic sites (Lan et al., 2001; Tovar and Westbrook, 2002) . Therefore, orexin A-mediated potentiation of NMDAR EPSCs might be due to movement of NMDARs from intracellular or extrasynaptic sites to the synapse. Because MK-801 is an activity-dependent and irreversible NMDAR antagonist (Rosemund et al., 1993) , we took advantage of its properties to block only synaptic NMDARs that opened in response to synaptically released glutamate. We applied MK-801 (10 mM; Tovar and Westbrook, 2002) to VTA slices in the absence of stimulation to equilibrate bath concentration. MK-801 progressively blocked NMDAR-EPSCs during the 0.1 Hz stimulation. Approximately 5% of the current remained after MK-801 application. We then washed out the unbound MK-801 in the absence of stimulation for 40 min in control neurons (n = 5). In a separate group of slices, we applied orexin A (100 nM, n = 6) for 5 min during the washout period. Next, we stimulated synaptic activity and observed that the maximal NMDAR amplitude in orexin A-treated neurons was significantly greater than in controls (Figures 4A and 4B, maximum current orexin: 40% 6 17%, control: 5% 6 1%, p < 0.05). In another set of experiments, we first coapplied NMDA (500 mM) with MK-801 (20 mM) to block all synaptic and extrasynaptic (C) Orexin A-mediated potentiation was mostly blocked in the presence of the selective NR2A inhibitor Zn 2+ (300 nM, n = 5). (D) Orexin A-mediated potentiation was not affected after bath application of the NR2B subunit-selective antagonist ifenprodil (3 mM; n = 6). (E) After NVP-AAM077 (0.4 mM) and ifenprodil (3 mM) coapplication, orexin A (100 nM) potentiation of NMDAR EPSCs was blocked (n = 6). (F) After coapplication of NVP-AAM077 (0.4 mM) and ifenprodil (3 mM), PPDA (1 mM) further inhibited NMDAR current and blocked orexin A (100 nM) mediated NMDAR potentiation (n = 6). Error bars represent SEM.
NMDARs. Then, we applied orexin A for 5 min during the washout of MK-801 and NMDA in the absence of stimulation ( Figures 4C and 4D ). After 15 min washout of orexin, we stimulated synaptic activity and found the maximal NMDAR amplitude in orexin A-treated neurons was again significantly greater than in controls ( Figures  4C and 4D , maximum current orexin: 20% 6 2%, n = 6; control: 7% 6 2%, n = 6, p < 0.05). These data indicate that orexin A potentiates NMDAR EPSCs, at least partially, by promoting movement of intracellular NMDARs to the synapse.
Orexin A Causes Late-Phase AMPAR-Mediated Plasticity and Facilitates Cocaine-Induced Potentiation of Excitatory Inputs to VTA Neurons Psychostimulants produce a form of experience-dependent plasticity known as behavioral sensitization, whereby animals exhibit a long-lasting increase in the locomotor-activating effects of the drug. This drug-induced locomotor effect is accompanied by increased motivation for drug intake and enhanced drug reward (Shippenberg and Heidbreder, 1995; Nestler, 2001; Kim et al., 2004) . Behavioral sensitization is mediated by increased synaptic output of VTA dopamine neurons and alterations of dopamine and glutamate effects in the nucleus accumbens and prefrontal cortex (Vanderschuren and Kalivas, 2000) . Potentiation of NMDARs is critical for the development of cocaine-mediated behavioral sensitization, and long-term plasticity at excitatory synapses can be observed with cocaine treatment (Vanderschuren and Kalivas, 2000) . This long-term plasticity is evident as a persistent increase in the ratio of AMPA to NMDAmediated synaptic currents of VTA neurons (Ungless et al., 2001; Saal et al., 2003; Borgland et al., 2004) .
We investigated whether orexin signaling in the VTA is required for the long-term plasticity associated with the development of behavioral sensitization. We examined long-term synaptic plasticity at excitatory synapses on VTA neurons 24 hr after a 5 day treatment of cocaine (15 mg/kg) or saline (0.9%), a time course shown to induce long-lasting locomotor sensitization to cocaine (Thomas et al., 2001) , with or without the OXR1 antagonist SB 334867 (10 mg/kg, Figure 5 ). To assay for synaptic plasticity, we compared the relative contribution of AMPARs and NMDARs to EPSCs recorded in VTA dopamine cells. Consistent with the potentiation observed following acute and 7 day cocaine treatments (Borgland et al., 2004) , 5 day treatment with cocaine potentiated the AMPAR/NMDAR ratio compared to saline controls ( Figure 5A , saline: 0.4 6 0.07, n = 4; cocaine: 0.8 6 0.1, n = 4, p < 0.05). This potentiation of synaptic plasticity was blocked by 5 day treatment with the OXR1 antagonist SB 334867 administered 15 min prior to cocaine or saline ( Figure 5A , saline + SB334867: 0.4 6 0.02, n = 5 versus cocaine + SB334867: 0.5 6 0.08, n = 11, p > 0.05). Since OXR1 antagonists block cocainemediated potentiation of the AMPAR/NMDAR ratio, orexin A may either facilitate cocaine-mediated synaptic plasticity or enhance synaptic transmission itself. We tested whether a 5 min orexin A application caused changes in AMPAR/NMDAR ratio either 15 min or 3-4 hr after application ( Figure 5B ). Orexin A (100 nM) decreased AMPAR/NMDAR ratio 15 min after treatment (control: 0.44 6 0.06, n = 8 versus 15 min: 0.29 6 0.04, n = 8, p < 0.05) and significantly increased it after 3-4 hr (0.75 6 0.1, n = 8, p < 0.01, Figure 5B) .
Next, to investigate whether AMPAR function and/or number was modified with orexin A treatment, we examined AMPAR-mediated miniature EPSCs (mEPSCs), a standard method for determining the locus of synaptic change. Compared to untreated neurons, orexin A (100 nM) caused a significant increase in both amplitude (Figures 6C , 6D, and 6F) and frequency ( Figures 6C, 6E , and 6G) 3-4 hr after application (24 6 1.6 pA; 2.4 6 0.5 Hz; n = 7 versus control: 13 6 1.3 pA; 0.93 6 0.16 Hz; n = 7; Figure 6A ), but not at 15 min (15 6 1.7 pA; 0.9 6 0.1 Hz; n = 6, p < 0.05, Figure 6B ). Interestingly, the increase in AMPAR mEPSC amplitude observed 3-4 hr after orexin A application was significantly reduced when the NMDAR antagonist APV (50 mM) was applied 3 min prior and during orexin application (16 6 0.6 pA, Figure 6D , n = 7, p > 0.05). However, frequency remained elevated over controls 3-4 hr after orexin A application (1.6 6 0.3 Hz, Figure 6E , n = 7, p < 0.05), suggesting that orexin application may also produce a distinct presynaptic effect.
When AMPA (2 mM for 30 s) in the presence of cyclothiazide (100 mM; to reduce AMPAR desensitization) was superfused onto neurons 15 min after orexin A (100 nM) treatment, there was no significant increase in AMPAR-induced current (2243 6 79 pA, n = 5) compared with untreated neurons (2210 6 64, n = 9, Figure 6H , p > 0.05). AMPAR-induced currents significantly increased 3-4 hr after orexin A (100 nM) treatment (2367 6 63 pA, n = 6, p < 0.05, Figure 6I , t test of peak control versus peak orexin).
To examine changes in number or function of NMDARs after orexin treatment, we recorded NMDAR mEPSCs in buffer without Mg 2+ and in the presence CNQX (10 mM), glycine (20 mM), and lidocaine (500 mM). Orexin A (100 nM) caused a significant increase in amplitude in NMDAR mEPSCs 15 min after application (17.1 6 0.7 pA, n = 8, Figures 7B, 7D , and 7F) compared to untreated neurons (14.2 6 0.9 pA, n = 8, Figures 7A, 7D , and 7F) or at 3-4 hr after orexin A application (13.9 6 0.5 pA, n = 7, Figures 7C, 7D , and 7F). Our results show that the frequency of NMDAR mEPSCs was not significantly altered by orexin A treatment (control: 2.1 6 0.3, 15 min: 2.1 60.3, 3-4 hours: 2.5 6 0.4, p > 0.05, Figures 7E and 7G) .
As a final test to determine at what time point after orexin treatment NMDARs were altered, we bath applied NMDA (50 mM, 30 s) and recorded the change in holding current. We observed a significant increase in NMDA-induced current 15 min after orexin A (100 nM) application (orexin A: 344 6 27 pA, n = 7; control: 245 6 43, n = 9, p < 0.05, Figure 7H ), but not after 3-4 hr (orexin A: 305 6 59, n = 6; p > 0.05, Figure 7I ). Taken together, these results indicate that the number or function or both of AMPARs are altered 3-4 hr after orexin A exposure, suggesting that orexin A may cause a late-phase long-term potentiation.
Orexin Signaling in the Ventral Tegmental Area Is Required for Behavioral Sensitization to Cocaine
Because orexin A potentiated NMDAR-mediated synaptic responses in dopamine neurons of the VTA, and synaptic plasticity at excitatory synapses after chronic cocaine treatment was blocked with coinjections of the OXR1 antagonist, we hypothesized that orexin receptor Cocaine treatment (n = 4) increased the AMPAR/NMDAR ratio compared to the saline-treated rats (n = 4, p < 0.05, t test). In the presence of preadministered SB 334867 (10 mg/kg, i.p.), cocaineinduced enhancement of the AMPAR/ NMDAR ratio, measured in VTA slices 24 hrs later, was blocked by SB 334867 (saline, n = 5; cocaine, n = 11, p > 0.05, t test). (B) Orexin A (100 nM) was bath applied for 5 min, and slices were recorded 15 min later or at 3-4 hr after orexin application. AMPAR/ NMDAR ratio was significantly increased 3-4 hr after orexin A application (n = 8) compared to control (n = 8) or 15 min after orexin A exposure (n = 8, p < 0.01). Bars represent mean and SEM.
activation contributes to the development of behavioral sensitization to cocaine.
To determine whether orexin signaling plays a role in behavioral sensitization to cocaine, we injected either the OXR1 antagonist SB 334867 (10 mg/kg, i.p.) or vehicle, 15 min prior to injecting cocaine (15 mg/kg, i.p) or saline (0.9%), and then placed rats in an open-field chamber to measure locomotor activity for 1 hr each day for 5 days. Interestingly, SB 334867 significantly blocked the development of sensitization, as the distance traveled on day 5 was 8504 6 2564 cm compared to 20347 6 5643 cm in cocaine-only-treated rats (Figure 8A , n = 13, p < 0.05). There was no significant difference in locomotor activity of cocaine-treated rats on day 1 between SB334867 (3579 6 1079 cm, n = 11) and vehicle (5692 6 1579 cm, n = 13) administered rats (p > 0.05). Further, SB 334867 did not reduce baseline locomotor activity ( Figure 8A , n = 13, p > 0.05).
We have provided evidence that orexin A signaling is required for acquisition of cocaine sensitization. However, our experiments have not answered the question of whether orexin A contributes to the expression of Orexin A (100 nM) was bath applied for 5 min and then recorded 15 min or 3-4 hr after orexin A application. Example traces of mEPSCs and averaged mEPSCs from the same cell are shown (A) without orexin. (B) 15 min after or (C) 3-4 hr after orexin A application. Scale bars, 20 pA, 100 ms for mEPSC traces and 5 pA, 5 ms for averaged mEPSCs. (D) Neurons recorded 3-4 hr after orexin A application had increased AMPAR mEPSC amplitude (n = 7, filled bars) compared to 15 min after (n = 6, shaded bars) or controls (n = 7, open bars, p < 0.05). The orexin-mediated increase in amplitude at 3-4 hr was blocked when APV (50 mM) was applied 3 min prior to and during orexin application (n = 7, dotted bars, p > 0.05). (E) AMPAR mEPSC frequency increased in neurons recorded 3-4 hr after orexin A application (n = 7) compared to 15 min after (n = 6) or control (n = 7) conditions (p < 0.05). AMPAR mEPSC frequency at 3-4 hr was also elevated with prior APV treatment (n = 7, p < 0.05). (F) A cumulative probability plot of amplitude for mEPSCs from example cells in control (black), 15 min (red), 3-4 hr (blue), or 3-4 hr after orexin A (100 nM) application with prior APV (50 mM) treatment (green). (G) A cumulative probability of frequency plot for mEPSCs from example cells in control, 15 min, 3-4 hr, or 3-4 hr after orexin application with prior APV (50 mM) treatment (green). (H) Changes in holding current were measured after bath application of AMPA (2 mM) in the presence of cyclothiazide (100 mM). There was no change in current when AMPA (2 mM) was superfused onto slices for 30 s between controls (n = 9) and neurons recorded 15 min after orexin A application (n = 5, p > 0.05). (I) Bath application of AMPA (2 mM) elicited a greater inward current in neurons recorded 3-4 hr after orexin A application compared to controls (n = 6, p < 0.05). Error bars represent SEM. cocaine sensitization. Therefore, to determine whether expression of cocaine sensitization requires release of orexin acting at the OXR1 receptor, we injected the OXR1 antagonist SB 334867 (10 mg/kg) with cocaine (15 mg/kg) on day 6 into either cocaine-sensitized or saline-treated rats. Locomotor activity on day 6 was not significantly reduced by SB 334867 ( Figure 8A , n = 7 in each group, p > 0.05), indicating that while orexin signaling is required for the development of cocaine sensitization it is not required for its expression.
Our in vitro experiments indicated that VTA was an important site of action for orexin-induced plasticity. Thus, to determine whether OXR1 antagonist blockade of locomotor sensitization to cocaine occurred through a direct action in the VTA, we repeated cocaine-sensitization experiments using a 7 day sensitization paradigm, but microinjected the OXR1 antagonist (6 mg/hemisphere) directly into the VTA prior to cocaine injection (15 mg/kg). Figure 8B shows that daily intra-VTA injection of the OXR1 antagonist abolished the development of locomotor sensitization to cocaine ( Figure 8B ; p > 0.05 in SB 334867-treated group, comparing day 7 and day 1 locomotor activity). Control animals injected with vehicle solution showed robust sensitization ( Figure 8B ; Orexin A (100 nM) was bath applied for 5 min and then recorded 15 min or 3-4 hr after orexin A application. NMDAR mEPSCs were recorded in Mg 2+ -free aCSF with 20 mM glycine, 10 mM CNQX, and 500 mM lidocaine when the neurons were voltage clamped at 240 mV. Example traces of mEPSCs were recorded (A) without orexin, (B) 15 min after, or (C) 3-4 hr after orexin A application. Scale bars, 50 pA, 100 ms. Below each condition is an averaged mEPSC from each of the above example neurons. Scale bars, 5 pA, 5 ms. (D) Orexin A increased NMDAR mEPSC amplitude 15 min after orexin A (100 nM) application (n = 8) compared to controls (n = 8) or 3-4 hr after orexin A application (n = 7, p < 0.05). (E) NMDAR mEPSC frequency was not altered by orexin A (100 nM) application (p>0.05). (F) A cumulative probability of amplitude plot for NMDAR mEPSCs from a single cell in control (black), 15 min (red), or 3-4 hr (blue) after orexin application. (G) A cumulative probability of frequency plot for mEPSCs from a single cell in control (black), 15 min (red), or 3-4 hr (blue) after orexin application. (H) Changes in holding current were measured after NMDA (50 mM, 30 s) was bath applied to VTA slices. NMDA-induced current was significantly greater in neurons 15 min after orexin A treatment (n = 7) compared to controls (n = 9, p < 0.05). (I) There was no difference in NMDA-induced current between controls and neurons 3-4 hr after orexin A treatment (n = 6, p > 0.05). Error bars represent SEM. p < 0.01, locomotor activity was significantly higher on days 4-7 relative to day 1). Mean locomotor distance was 34162 6 4477 cm on day 7 in control animals ( Figure 8C ), compared with 19274 6 4559 cm in OXR1 antagonist-treated animals ( Figure 8D ), the latter value not differing significantly from the locomotor distance traveled on day 1. Similar to systemic injections (Figure 8A) , a single intra-VTA injection of the OXR1 antagonist did not affect expression of pre-existing cocaine sensitization in this control group (p > 0.05; data not shown). Taken together, our results indicate that OXR1 activation at dopaminergic neurons in the VTA is required for the development of behavioral sensitization as well as for the induction of synaptic plasticity at excitatory synapses associated with sensitization.
Discussion
The data presented here establish a function for orexin signaling as a critical substrate for plasticity of synaptic inputs to dopamine neurons of the VTA. Four observations support this conclusion. First, in vitro application of orexin A induces potentiation of NMDAR responses in VTA dopamine neurons. Second, the OXR1 receptor antagonist SB 334867 blocks induction of cocaineinduced potentiation of excitatory inputs onto VTA neurons. Third, orexin A causes late-phase increases in AMPAR-mediated synaptic transmission. Fourth, microinjection of SB 334867 directly into the VTA blocks the development of cocaine-induced locomotor sensitization. These data provide evidence that orexin signaling pathways play an important role in drug-induced neural plasticity contributing to cocaine addiction.
Orexin A Enhances Synaptic Strength in VTA Dopamine Neurons Orexin A potentiated NMDAR EPSCs in dopamine neurons via activation of OXR1 receptors and stimulation of PKC/PLC signal transduction pathways. These results are consistent with orexin A-mediated PLC and PKC activation of Ca 2+ signaling, observed in isolated VTA neurons (Uramura et al., 2001 ) through OXR1, that are coupled to Gq-type Ga proteins (Zhu et al., 2003) . The orexin A-mediated synaptic plasticity resulted from the translocation of NMDARs to the synapse. Because we observed an increase in NMDAR-evoked EPSCs after orexin treatment compared to controls after blocking all synaptic and extrasynaptic NMDARs, it appears that the orexin-mediated potentiation of NMDARs is mediated, at least in part, by movement of NMDARs from intracellular compartments to the synapse. Movement of NMDARs to synaptic sites could provide a mechanism for rapidly enhancing synaptic strength (Tovar and Westbrook, 2002) . This is consistent with orexin A potentiation of synaptic strength by movement of NMDARs into the synapse with a time course on the order of minutes.
Experiments with orexin A application in the presence of NMDAR subunit inhibitors suggest that NR2A-containing NMDARs play a significant role in enhancing NMDAR-mediated responses. In rats aged P21 or older, mRNA and protein for NR2A, NR2B, and to a lesser extent NR2C and NR2D has been observed in midbrain (Monyer et al., 1994; Dunah et al., 1996) ; however, NR2A was not observed in the rat substantia nigra (Jones and Gibb, 2005; Standaert et al., 1994) . NMDAR subunit composition in rat VTA has not been reported. In VTA punches, our lab has found protein for NR2A, NR2B, and NR2C (B. Schilstrom and A. Bonci, 2002 , Soc. Neurosci., abstract). NR2D could not be detected due to the lack of selectivity of the antibody. The selectivity of the NR2A/C antagonist has been questioned (Berberich et al., 2005; Weitlauf et al., 2005) because preapplication of 0.4 mM NVP-AAM077 has been demonstrated to inhibit NR2B-containing NMDARs (Weitlauf et al., 2005) . However, in our experiments, three lines of evidence suggest that orexin A can recruit NMDAR subtypes. First, NVP-AAM077 blocked NMDAR potentiation postorexin A application. Second, Zn 2+ , a selective inhibitor of NR2A-containing NMDARs at nanomolar concentrations, blocked orexin-mediated potentiation of NMDARs. Finally, the NR2B subunit antagonist ifenprodil exerted no significant effect on orexin A-mediated potentiation of NMDAR EPSCs. The residual orexin-mediated NMDAR potentiation observed in the presence of NVP-AAM077 or Zn 2+ was blocked by coapplication of ifenprodil, NVP-AAM077, and the NR2C/D-preferring antagonist PPDA. These data suggest that although orexin A primarily potentiates NR2A-containing NMDAR receptors, it can also potentiate other NR2 subunits to a lesser extent. Thus, orexin A appears to be enhancing synaptic plasticity in the VTA primarily by promoting increased NR2A-containing NMDARs at the synapse.
Our results indicate that acute orexin A application produces a PLC/PKC-dependent potentiation of NMDARmediated responses, while AMPAR-mediated responses are unaffected. Further, we have shown that in vivo exposure to cocaine produces a delayed potentiation of AMPARs but not NMDARs (Ungless et al., 2001; Borgland et al., 2004; present study) , which is blocked by the OXR1 antagonist SB 334867. Therefore, it is possible that the orexin-mediated potentiation of NMDARs facilitates the induction of synaptic plasticity, which involves an increase in AMPAR-mediated synaptic transmission. Although we did not see a change in AMPARevoked EPSCs, mEPSCs, or AMPAR current changes at 15 min after orexin application, by 3-4 hr a robust increase in AMPAR-mediated synaptic transmission had developed. This late-phase increase in postsynaptic AMPAR-mediated synaptic transmission was blocked when the NMDAR antagonist APV was coadministered with orexin A. The increase in AMPAR mEPSC frequency was not blocked by APV, suggesting that an NMDAR-independent delayed presynaptic effect may also occur. Consistent with our results, orexin A has previously been shown to enhance long-term potentiation when applied directly to the dentate gyrus in anesthetized rats (Wayner et al., 2004) . Increased synaptic efficacy may be due to insertion of new AMPARs into the synaptic membrane (Malinow et al., 2000; Lu et al., 2001) or other structural or functional modifications at existing AMPAR channels (Benke et al., 1998; Derkach et al., 1999) . Additionally, late-phase long-term potentiation occurring 3-5 hr after stimulation is dependent on postsynaptic protein synthesis (Nayak et al., 1998; Grosshans et al., 2001) . Therefore, the delayed increase in AMPARmediated synaptic transmission after orexin A application may represent late-phase long-term potentiation.
Orexin May Play a Critical Role in Addiction
The present study demonstrates that orexin A produces long-lasting plasticity at excitatory synapses of dopamine neurons in the VTA. Synaptic plasticity in the VTA has been suggested to play an important role in the behavioral consequences of in vivo exposure to drugs of abuse (Robinson and Berridge, 1993; Overton and Clark, 1997; Ungless et al., 2001; Saal et al., 2003) . From a functional perspective, NMDARs perform two major roles in VTA dopamine neurons: they are necessary for the induction of in vitro long-term potentiation (Bonci and Malenka, 1999; Overton et al., 1999) and they promote burst firing of dopamine neurons Overton and Clark, 1992; Komendantov et al., 2004) . Previous studies have suggested that burst firing of VTA dopamine neurons encodes the occurrence of salient stimuli (Schultz, 2002) . As a consequence, burst firing increases extracellular dopamine in the projection areas more efficiently than when dopamine neurons fire regularly spaced trains of action potentials (Gonon, 1988; Komendantov et al., 2004) . Although dopamine neurons generally fire in a pacemaker-like fashion in vitro, burst-firing patterns, similar to what has been observed in vivo, can be reproduced by bath application of NMDA (Komendantov et al., 2004) . Thus, an increase in synaptic efficacy, including the synaptic potentiation observed in this study, may contribute to the increase in dopamine cell firing rate. This change could enhance reinforcement, as it has been proposed that dopamine neuronal firing represents a teaching signal (Garris et al., 1999; Schultz, 2002) . Accordingly, orexin A has been demonstrated to increase firing rate and in some cases cause burst firing of VTA dopamine neurons in rat brain slices (Korotkova et al., 2003) , although it remains to be determined whether this firing is dependent on potentiation of glutamatergic synapses. Orexin potentiation of NMDAR currents in dopamine neurons may represent a crucial process underlying stimulation of locomotor activity to achieve goal-directed behavior. For example, fasted animals increase wakefulness and locomotor activity via activation of orexin neurons , and this locomotor activation may be dopamine dependent (Wisor et al., 2001) . We have demonstrated that orexin A signaling is required for the acquisition of cocaine sensitization, a paradigm for craving, suggesting that by blocking orexin signaling in the VTA, we may be perturbing cocaine's motivational significance and reducing the rat's drive for cocaine seeking.
Animals with lesions in the LH exhibit hypophagia and somnolence (Levitt and Teitelbaum, 1975; Bernardis and Bellinger, 1996) , suggesting important roles for the LH in the control of motivated behavior. The LH has also been implicated in motivation associated with reward (Wise 1996; Di Leone et al., 2003) . Direct electrical stimulation of the LH is so intensely rewarding to rats that they will starve themselves when limited access to such stimulation is given concurrently with limited access to food (Routtenberg and Lindy, 1965) . Furthermore, drugs of abuse potentiate the rewarding effects of LH self-stimulation (Wise, 1996) . Recent studies have shown that some of these LH functions may require orexin neurons, as orexin knockout mice show reduced morphine dependence . Additionally, activation of orexin neurons is strongly linked to preferences for cues associated with drug and food reward, as both activation of orexin neurons and intra-VTA administration of orexin A leads to a reinstatement of an extinguished conditioned place preference to morphine (Harris et al., 2005) . Therefore, it is a strong possibility that orexin A-induced synaptic plasticity in the VTA is mediating reward-seeking behaviors. The findings presented here establish a potential mechanism for the role of orexin signaling in plasticity related to addiction. Our results demonstrate that orexin A induces synaptic plasticity in dopaminergic VTA neurons; moreover, this form of synaptic plasticity is likely an important substrate of behaviors relevant to addiction, as we show that activation of OXR1 receptors in the VTA is necessary for the development of cocaine-mediated behavioral sensitization. Thus, orexin receptors may provide novel pharmacotherapeutic targets for motivational disorders such as addiction.
Experimental Procedures Electrophysiology
All the electrophysiological recordings were performed in rats ranging from P21 to P30. Briefly, rats were anesthetized with halothane and sacrificed. Horizontal sections of the VTA (230 mM) were prepared with a vibratome (Leica, Nussloch, Germany). Slices were placed in a holding chamber and allowed to recover for at least 1 hr before being placed in the recording chamber and superfused with bicarbonate-buffered solution (ACSF) saturated with 95% O 2 / 5% CO 2 and containing (in mM): 119 NaCl, 1.6 KCl, 1.0 NaH 2 PO 4 , 1.3 MgCl 2 , 2.5 CaCl 2 , 26.2 NaHCO 3 , and 11 glucose (at 32ºC-34ºC). Picrotoxin (100 mM) was added to block GABA A receptor-mediated inhibitory postsynaptic currents. Cells were visualized using infrared differential interference contrast video microscopy. Whole-cell voltage-clamp recordings were made using an Axopatch 1D amplifier (Axon Instruments, Union City, CA). Electrodes (2.8-4.0 MU) contained (in mM): 120 cesium methansulfonate, 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA-Cl, 2.5 MgATP, and 0.25 NaGTP (pH 7.2-7.3) (270-285 mOsm). Series resistance (10-40 MU) and input resistance were monitored online with a 4 mV depolarizing step (50 ms) given just after every afferent stimulus. Dopaminergic VTA neurons were identified by the presence of a large I h current (Lacey et al., 1990; and, in some cases, tyrosine hydroxylase labeling. A bipolar stimulating electrode was placed 100-300 mm rostral to the recording electrode and was used to stimulate excitatory afferents at 0.1 Hz. Neurons were voltage clamped at -70 mV and +40 mV to record AMPAR-and NMDAR-mediated EPSCs. EPSCs were filtered at 2 kHz, digitized at 5-10 kHz, and collected online using Igor Pro software (Wavemetrics, Lake Oswego, OR). NMDAR or AMPAR traces were constructed by averaging 12 EPSCs (120 s) elicited at +40 mV or at 270 mV. NMDAR amplitude was measured 20 ms after the stimulus artifact, when the EPSC is primarily NMDAR mediated.
To calculate the AMPAR/NMDAR ratio, an average of 12 EPSCs at +40 mV was computed before and after application of the NMDAR blocker AP5 (50 mM) for 5 min. NMDAR responses were calculated by subtracting the average response in the presence of AP5 (AMPAR only) from that seen in its absence; the peak of the AMPAR EPSC was divided by the peak of the NMDAR EPSC to yield an AMPAR/ NMDAR ratio.
AMPAR mEPSCs were recorded in cells voltage clamped at 270 mV in lidocaine (500 mM), APV (50 mM), and sucrose (100 mM). NMDAR mEPSCs were recorded at 240 mV in Mg 2+ -free external solution with lidocaine (500 mM), glycine (20 mM), and CNQX (10 mM). mEPSCs were collected using Clampex (Axon Instruments) and analyzed using Mini Analysis Program (Synaptosoft). Detection criteria were set at >10 pA, <1 ms rise-time, and <3 ms decay-time for AMPAR mEPSCs and >10 pA, <1 ms rise-time, and <10 ms decay-time for NMDAR mEPSCs. mEPSC traces were recorded while sampling every 10 ms, the images were filtered at 5 kHz. Averaged mEPSCs were constructed using Mini Analysis Program (Synaptosoft).
Treatment Regimen and Locomotor Activity
Male Sprague-Dawley Rats (P21-P30; Charles River, NC) were singly housed with food and water available ad libitum. A 12 hr light/ dark cycle was used, with the lights on at 7:00 A.M. All cocaine injections and behavioral testing were performed during the light cycle for consecutive days. The four treatment groups consisted of rats given five daily i.p. injections of SB 334867 (10 mg/kg) 15 min preceding i.p. injection of cocaine (15 mg/kg) or saline (0.9% NaCl), or i.p. injections of vehicle (10% DMSO and 25% b-hydroxy cyclodextrin in saline) 15 min preceding i.p. injection of cocaine or saline. All animals were habituated to the photocell boxes (Med Associates, St. Albans, VT) for 2 hr prior to the start of the experiment. All animals were further habituated to the photocell boxes for 30 min prior to 60 min testing session. Locomotor activity was measured in 17 inch 3 17 inch chambers lined with three 16-beam I/R arrays. A 50 ms scanning rate was used for measurement of beams broken. Distance traveled was measured using Open Field Activity Software (Med Associates, Inc) and analyzed for estimates of locomotion based on the movement of a given distance and resting delay (movement in a given period of time).
Intra-VTA injections and Locomotor Activity
Male Sprague-Dawley rats (250 grams) were implanted with bilateral cannulae directed at the VTA (AP, 25.2; ML, 60.5; DV, 28.0). Following recovery from surgery, animals were tested in a cocaine-sensitization assay similar to that used for systemic administration of the OXR1 antagonist, but with two changes: a 7 day sensitization paradigm was used, and the OXR1 antagonist SB 334867 was microinjected directly into the VTA (6 mg/hemisphere in 300 nL solution composed of 10% DMSO in water). All other methods for habituation and data collection were identical to that described above. Rats were deeply anesthetized with pentobarbital and perfused with a 10% formaldehyde solution. Brains were cryoprotected in 25% sucrose, 40 mm coronal sections were cut on a freezing microtome, and sections were mounted, dried, and coverslipped. Injection sites were located under a light microscope and recorded on atlas figures adapted from Paxinos and Watson (1997) .
Data Analysis
All values are expressed as mean 6 SEM. Statistical significance was assessed using two-tailed Student's t tests or a one-way ANOVA for multiple group comparisons. A Bonferroni post hoc test following an ANOVA was used to test significant differences between multiple groups.
